Eva Altrock

Title: Eva Altrock: Innovator in Myeloid Malignancies Treatment

Introduction

Eva Altrock is a prominent inventor based in Vaihingen/Enz, Germany. She has made significant contributions to the field of medical research, particularly in the treatment of myeloid malignancies. Her innovative work focuses on the development of lysyl oxidase inhibitors, which have the potential to transform therapeutic approaches in oncology.

Latest Patents

Eva Altrock holds a patent for "Lysyl oxidase inhibitors for treating myeloid malignancies." This patent encompasses lysyl oxidase (LOX) inhibitors, lysyl oxidase-like (LOXL) inhibitors, and pharmaceutically acceptable salts thereof. The methods described in her patent involve administering a therapeutically effective amount of these inhibitors, either alone or in combination with a second therapeutic agent, to treat myeloid malignancies.

Career Highlights

Throughout her career, Eva has demonstrated a commitment to advancing medical science. Her work at Syntara Limited has positioned her as a key player in the development of novel therapeutic strategies. With her expertise, she has contributed to the understanding and treatment of complex diseases.

Collaborations

Eva collaborates with notable colleagues, including Wolf-Karsten Hofmann and Daniel Nowak. These partnerships enhance her research efforts and contribute to the innovative solutions being developed in her field.

Conclusion

Eva Altrock's contributions to the treatment of myeloid malignancies through her innovative patent work exemplify her dedication to improving patient outcomes. Her ongoing research and collaborations continue to pave the way for advancements in medical therapies.